BAXTER INTERNATIONAL INC. |
Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
| 34,1 USD | +2,90 % |
|
+0,59 % | -11,80 % |
| 29.05. | Baxter International Inc. gibt neue Daten zur erweiterten Hamodialyse, bekannt als HDX-Therapie, bekannt | CI |
| 22.05. | BAXTER INTERNATIONAL INC. : Citigroup klebt neutral | ZM |
Kurzporträt
- Arzneimittel und Medizinprodukte (33,8%): Produkte zur Behandlung von Hämophilie (Substitutionsgerinnungsfaktoren) und Immundefekten (Mehrzweck-Immunglobine), für die Intensivpflege (Humanalbumin) und die Biochirurgie (Fibrinkleber, chirurgisches Gel, Knochenersatzstoffe, hämostatische Kompressen usw.);
- Medikamente und Ausrüstung für die Nierendialyse (30,1%);
- Systeme für die Verabreichung von Medikamenten und die intravenöse Therapie (15,2%): in den Bereichen Anästhesie, Onkologie (Chemotherapie und Bestrahlung), parenterale Ernährung usw. verwendet;
- Sonstiges (20,1%).
Der Export macht 52,7% des Nettoumsatzes aus.
Mitarbeiterzahl: 60 000
Umsatz nach Geschäftsbereich
| USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
Medical Products and Therapies
33,8
%
| - | - | 5 011 | 33,8 % | - |
Kidney Care
30,1
%
| - | - | 4 453 | 30,1 % | - |
Healthcare Systems and Technologies
20,3
%
| - | - | 3 013 | 20,3 % | - |
Pharmaceuticals
15,2
%
| - | - | 2 249 | 15,2 % | - |
Other
0,6
%
| - | - | 87 | 0,6 % | - |
Umsatz je Region
| USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
United States
47,3
%
| 7 223 | 47,8 % | 7 000 | 47,3 % | -3,09 % |
Rest of World
30,3
%
| - | - | 4 494 | 30,3 % | - |
Emerging Markets
22,4
%
| - | - | 3 319 | 22,4 % | - |
Manager
| Manager | Titel | Alter | Seit |
|---|---|---|---|
Joe Almeida
CEO | Chief Executive Officer | 61 | 01.10.15 |
Joel Grade
DFI | Director of Finance/CFO | 54 | 18.10.23 |
Reaz Rasul
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.17 |
Tobi Karchmer
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.19 |
Heather Knight
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.19 |
Clare Trachtman
IRC | Investor Relations Contact | - | 01.01.00 |
David Rosenbloom
LAW | General Counsel | - | 01.01.22 |
Darren Evans
PRN | Corporate Officer/Principal | - | 01.12.21 |
Heather Wechet
HRO | Human Resources Officer | - | 01.06.08 |
Lynn Pawelski
LAW | General Counsel | - | 01.04.18 |
Aufsichtsräte
| Aufsichtsräte | Titel | Alter | Seit |
|---|---|---|---|
Stephen Oesterle
BRD | Director/Board Member | 73 | 06.02.17 |
Peter Wilver
BRD | Director/Board Member | 64 | 10.05.22 |
| Director/Board Member | 64 | 18.02.19 | |
| Director/Board Member | 63 | 01.01.19 | |
Joe Almeida
CEO | Chief Executive Officer | 61 | 01.10.15 |
Catherine Smith
BRD | Director/Board Member | 60 | 18.07.17 |
| Director/Board Member | 69 | 13.12.21 | |
| Director/Board Member | 66 | 21.08.23 | |
David Wilkes
BRD | Director/Board Member | 67 | 15.02.21 |
D. Shafer
BRD | Director/Board Member | 66 | 10.05.22 |
Anteilsklasse
| Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
|---|---|---|---|---|---|
| Aktie A | 1 | 683 510 683 | 507 613 362 ( 74,27 %) | 173 930 493 ( 25,45 %) | 74,27 % |
Unternehmensbesitz
| Name | Aktien | % | Bewertung |
|---|---|---|---|
ALVOTECH 1,03% | 2 735 145 | 1,03% | 37 334 729 $ |
Unternehmenskontakt
Konzerngesellschaften
| Name | Kategorie und Branche |
|---|---|
Baxter (India) Pvt Ltd.
 Baxter (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology Baxter (India) Pvt Ltd. manufactures recombinant and plasma-based proteins that are used to treat hemophilia and other bleeding disorders in India. The firm also offers plasma based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shocks, and other chronic and acute blood related conditions. It offers products to healthcare professionals, patients, and caregivers in the areas of anaesthesia, biosurgery, clinical nutrition, critical care, haemophilia, infusion systems, pharmaceuticals and IV solutions, renal, kidney disease, and immune deficiency. The company is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Baxter (Malta) Trading Co. Ltd.
| |
Baxter World Trade SRL
 Baxter World Trade SRL Miscellaneous Commercial ServicesCommercial Services Founded in 1984, Baxter World Trade SRL is a Belgian company that provides management services. Part of Baxter International, Inc., the company is based in Lessines, Belgium. |
Miscellaneous Commercial Services
|
Gambro Lundia AB
 Gambro Lundia AB Medical DistributorsDistribution Services Gambro Lundia AB operates as a medical technology company. It develops, manufactures, and distributes products and treatments for kidney and liver dialysis, treatment of myeloma kidney, and other extracorporeal treatments for chronically and acutely ill patients. The firm also holds shares in other companies. The company was founded on February 18, 1953 and is headquartered in Lund, Sweden. |
Medical Distributors
|
Baxter R & D Europe SRL
 Baxter R & D Europe SRL Medical/Nursing ServicesHealth Services Founded in 1954, Baxter R & D Europe SRL is a subsidiary of Baxter International, Inc. that provides healthcare services. The company is based in Braine-l'Alleud, Belgium. |
Medical/Nursing Services
|
Baxter Pharmaceuticals India Pvt Ltd.
 Baxter Pharmaceuticals India Pvt Ltd. Chemicals: Major DiversifiedProcess Industries Founded in 2005, Baxter Pharmaceuticals India Pvt Ltd. is a subsidiary of Baxter International, Inc. that manufactures chemical products. The company is based in Ahmedabad, India. |
Chemicals: Major Diversified
|
Baxter Innovations & Business Solutions Pvt Ltd.
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
| % 1. Jan. | Kap. | |
|---|---|---|
| -11,80 % | 17,37 Mrd. | |
| -7,16 % | 178 Mrd. | |
| -1,23 % | 107 Mrd. | |
| -4,86 % | 67,04 Mrd. | |
| -4,28 % | 47,23 Mrd. | |
| +10,32 % | 44,62 Mrd. | |
| +8,14 % | 42,5 Mrd. | |
| +15,53 % | 25,22 Mrd. | |
| -5,88 % | 24,14 Mrd. | |
| -5,38 % | 23,69 Mrd. |
- Börse
- Aktien
- 853815 Aktie
- Unternehmen Baxter International Inc.
